Literature DB >> 28670454

Post-nano strategies for drug delivery: Multistage porous silicon microvectors.

Alessandro Venuta1,2, Joy Wolfram1,3, Haifa Shen1,4, Mauro Ferrari1,5.   

Abstract

Nanodelivery systems usually improve the biodistribution of drugs, leading to reduced side effects and enhanced therapeutic efficacy. However, only a small portion of the injected nanoparticle dose accumulates in pathological tissue. Challenges in drug delivery arise due to a multitude of transport obstacles in the body, including the endothelium, the extracellular matrix, and the cell membrane. In general, nanoparticles are designed to overcome only a few biological barriers, making them inadequate for localized drug delivery. Accordingly, a multifunctional and multicomponent systems are required to effectively address a wide variety of transport obstacles. A suitable approach to obtain high levels of multifunctionality is to bring together the nanoscale with the microscale, resulting in post-nano strategies for drug delivery. This review discusses several such post-nano approaches, with an emphasis on the multistage vector (MSV) platform. The MSV consists of three components on different spatial scales, each intended to address biological barriers that exist in a specific compartment in the body. The first stage vector is a microparticle that is designed to navigate in the vascular compartment. The second stage vector consists of nanoparticles that are released from the microparticle into the tissue interstitium, where they address biological barriers in extracellular and intracellular compartments. The final component of the system is a small molecule therapeutic agent. A new generation of microparticle-based strategies with expanded applications has recently been developed, including injectable nanoparticle generators and silicon particles for immunotherapy. Notably, the advantage of incorporating microstructures in drug delivery vehicles is apparent from the observation that superior functionality only appears on the microscale, highlighting the inherent functional limitations of nanostructures.

Entities:  

Year:  2016        PMID: 28670454      PMCID: PMC5489248          DOI: 10.1039/C6TB01978A

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  78 in total

1.  A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.

Authors:  Bronwyn Scott; Jianliang Shen; Sara Nizzero; Kathryn Boom; Stefano Persano; Yu Mi; Xuewu Liu; Yuliang Zhao; Elvin Blanco; Haifa Shen; Mauro Ferrari; Joy Wolfram
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

2.  Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model.

Authors:  Ying Chau; Natalie M Dang; Frederick E Tan; Robert Langer
Journal:  J Pharm Sci       Date:  2006-03       Impact factor: 3.534

3.  Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs.

Authors:  Jonathan O Martinez; Michael Evangelopoulos; Rohan Bhavane; Stefania Acciardo; Francesco Salvatore; Xuewu Liu; Mauro Ferrari; Ennio Tasciotti
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 4.  Reactive oxygen species in cancer.

Authors:  Geou-Yarh Liou; Peter Storz
Journal:  Free Radic Res       Date:  2010-05

Review 5.  What does physics have to do with cancer?

Authors:  Franziska Michor; Jan Liphardt; Mauro Ferrari; Jonathan Widom
Journal:  Nat Rev Cancer       Date:  2011-08-18       Impact factor: 60.716

Review 6.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

7.  Multifunctional porous silicon nanoparticles for cancer theranostics.

Authors:  Chang-Fang Wang; Mirkka P Sarparanta; Ermei M Mäkilä; Maija L K Hyvönen; Pirjo M Laakkonen; Jarno J Salonen; Jouni T Hirvonen; Anu J Airaksinen; Hélder A Santos
Journal:  Biomaterials       Date:  2015-02-11       Impact factor: 12.479

8.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

9.  An injectable nanoparticle generator enhances delivery of cancer therapeutics.

Authors:  Rong Xu; Guodong Zhang; Junhua Mai; Xiaoyong Deng; Victor Segura-Ibarra; Suhong Wu; Jianliang Shen; Haoran Liu; Zhenhua Hu; Lingxiao Chen; Yi Huang; Eugene Koay; Yu Huang; Jun Liu; Joe E Ensor; Elvin Blanco; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  Nat Biotechnol       Date:  2016-03-14       Impact factor: 54.908

10.  Drug-induced oxidative stress and toxicity.

Authors:  Damian G Deavall; Elizabeth A Martin; Judith M Horner; Ruth Roberts
Journal:  J Toxicol       Date:  2012-08-05
View more
  11 in total

1.  Clinical Cancer Nanomedicine.

Authors:  Joy Wolfram; Mauro Ferrari
Journal:  Nano Today       Date:  2019-03-06       Impact factor: 20.722

Review 2.  Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.

Authors:  Sara Busatto; Anthony Pham; Annie Suh; Shane Shapiro; Joy Wolfram
Journal:  Biomed Microdevices       Date:  2019-04-15       Impact factor: 2.838

Review 3.  Different Sourced Extracellular Vesicles and Their Potential Applications in Clinical Treatments.

Authors:  Leila Bahmani; Mujib Ullah
Journal:  Cells       Date:  2022-06-21       Impact factor: 7.666

Review 4.  Lipoprotein-based drug delivery.

Authors:  Sara Busatto; Sierra A Walker; Whisper Grayson; Anthony Pham; Ming Tian; Nicole Nesto; Jacqueline Barklund; Joy Wolfram
Journal:  Adv Drug Deliv Rev       Date:  2020-08-11       Impact factor: 15.470

Review 5.  Recent advances on smart glycoconjugate vaccines in infections and cancer.

Authors:  Marko Anderluh; Francesco Berti; Anna Bzducha-Wróbel; Fabrizio Chiodo; Cinzia Colombo; Federica Compostella; Katarzyna Durlik; Xhenti Ferhati; Rikard Holmdahl; Dragana Jovanovic; Wieslaw Kaca; Luigi Lay; Milena Marinovic-Cincovic; Marco Marradi; Musa Ozil; Laura Polito; Josè Juan Reina; Celso A Reis; Robert Sackstein; Alba Silipo; Urban Švajger; Ondřej Vaněk; Fumiichiro Yamamoto; Barbara Richichi; Sandra J van Vliet
Journal:  FEBS J       Date:  2021-06-01       Impact factor: 5.622

6.  Enhanced thermal effect of plasmonic nanostructures confined in discoidal porous silicon particles.

Authors:  Dechen Zhang; Hung-Jen Wu; Xinyu Zhou; Ruogu Qi; Li Xu; Yi Guo; Xuewu Liu
Journal:  RSC Adv       Date:  2020-08-20       Impact factor: 3.361

Review 7.  Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy.

Authors:  Yihui Zhai; Jinghan Su; Wei Ran; Pengcheng Zhang; Qi Yin; Zhiwen Zhang; Haijun Yu; Yaping Li
Journal:  Theranostics       Date:  2017-06-25       Impact factor: 11.556

8.  Extension of a multiphase tumour growth model to study nanoparticle delivery to solid tumours.

Authors:  Barbara Wirthl; Johannes Kremheller; Bernhard A Schrefler; Wolfgang A Wall
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240

9.  A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery.

Authors:  Joy Wolfram; Sara Nizzero; Haoran Liu; Feng Li; Guodong Zhang; Zheng Li; Haifa Shen; Elvin Blanco; Mauro Ferrari
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

Review 10.  Extracellular vesicle-based drug delivery systems for cancer treatment.

Authors:  Sierra Walker; Sara Busatto; Anthony Pham; Ming Tian; Annie Suh; Kelsey Carson; Astrid Quintero; Maria Lafrence; Hanna Malik; Moises X Santana; Joy Wolfram
Journal:  Theranostics       Date:  2019-10-17       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.